Get the latest news on Somaxon. Click any link to retrieve the press release in PDF format. (Adobe Acrobat Reader is required). If you don’t have Adobe Acrobat, download it for free from Adobe.
December 18,2006, Somaxon’s SILENOR™ Demonstrates Positive Results
in Long-Term Phase 3
Clinical Trial in Elderly Patients with Insomnia
• SILENOR™ Demonstrates Statistically Significant Improvement vs. Placebo in the Primary Endpoint, Wake After Sleep Onset (WASO), and Multiple Secondary Endpoints
• Represents Fourth Phase 3 Clinical Trial of SILENOR™ to Demonstrate Positive Results in the Treatment of Insomnia
• Somaxon on Track for New Drug Application (NDA) Filing in Q3 2007
San Diego, CA – Somaxon Pharmaceuticals, Inc. (NASDAQ:
SOMX) today announced positive results from the company’s Phase 3 clinical trial
evaluating SILENOR™ (doxepin HCl) in elderly patients with chronic primary insomnia. (.pdf)
December 17, 2006, Somaxon Pharmaceuticals to Announce Results of
Phase 3 Clinical Trial of SILENOR™
for the Treatment of Insomnia in Elderly Patients
and Host Conference Call
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (NASDAQ:
SOMX) today said that, tomorrow morning, Monday, December 18, the company plans
to issue results from its Phase 3 clinical trial of SILENOR™ (doxepin HCl) for the
treatment of insomnia in elderly patients. Additionally, Somaxon management will host
a conference call Monday morning at 9:00 a.m. Eastern Time to review the results of this
Phase 3 trial. (.pdf)
December 7, 2006, Somaxon Pharmaceuticals to Present at the RBC Capital Markets Healthcare Conference
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (NASDAQ:
SOMX) today announced that Ken Cohen, president and chief executive officer, will
participate in the panel discussion, “Satisfying the Search for Sleep,” at the RBC Capital
Markets Conference at The Westin New York at Times Square hotel, on Thursday, December
14, 2006, at 12:00 p.m. Eastern Time. (.pdf)
December 5, 2006, Somaxon Reports Results From a Clinical Trial of Oral Nalmefene in Pathological Gambling
SAN DIEGO, CA − Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced results from the company’s Phase 2/3 clinical trial evaluating 20 mg and 40 mg of oral nalmefene hydrochloride, an opiate antagonist, in patients with a diagnosis of pathological gambling. (.pdf)
November, 21, 2006, Somaxon Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced that Ken Cohen, president and chief executive officer, will present a company update at the Piper Jaffray Health Care Conference at The Pierre New York, on Friday, December 1, 2006, at 8:30 a.m. Eastern Time. (.pdf)
November, 20, 2006, Somaxon Pharmaceuticals’ SILENOR™ Demonstrates Positive Results in its
Third Phase 3 Clinical Trial in Insomnia
• SILENOR™ Demonstrates Statistically Significant Improvement vs. Placebo in the Primary Endpoint, Subjective Total Sleep Time (sTST), Through Four Weeks in Elderly Patients with Insomnia
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced positive results from the company’s Phase 3 clinical trial evaluating SILENOR™ (doxepin HCl) in elderly patients with primary sleep maintenance insomnia. (.pdf)
November 19, 2006,
Somaxon Pharmaceuticals to Announce Results of Phase 3 Clinical Trial of SILENOR™ for the Treatment of Insomnia in Elderly Patients and Host Conference Call
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today said that, tomorrow morning, Monday, November 20, the company plans to issue results from its Phase 3 clinical trial of SILENOR™ (doxepin HCl) for the treatment of insomnia in elderly patients. Additionally, Somaxon management will host a conference call Monday morning at 9:00 a.m. Eastern Time to review the results of this Phase 3 trial. (.pdf)
November 13, 2006, SOMAXON PHARMACEUTICALS NAMES BRIAN DORSEY
VICE PRESIDENT OF MANUFACTURING AND PROGRAM MANAGEMENT
SAN DIEGO, CA − Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced the appointment of Brian Dorsey as Vice President of Manufacturing and Program Management, a newly created position. Mr. Dorsey was previously the company’s Executive Director, Manufacturing and Program Management. (.pdf)
November 13, 2006, Somaxon Pharmaceuticals to Present at the BIOCOM San Diego Investor Conference and 2006 Credit Suisse Healthcare Conference
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced that it will present at the following two conferences:
BIOCOM San Diego Investor Conference
Wednesday, November 15, 2006, at 11:40 a.m. PT (2:40 p.m. ET)
2006 Credit Suisse Healthcare Conference
Friday, November 17, 2006, at 9:30 a.m. PT (12:30 p.m. ET)
(.pdf)
November 9, 2006, SOMAXON PHARMACEUTICALS REPORTS 2006 THIRD QUARTER FINANCIAL RESULTS
• Third quarter 2006 net loss of $9.8 million, or $0.55 per share
• Data from two remaining Phase 3 SILENOR™ (doxepin HCl) trials expected by end of 2006
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a
specialty pharmaceutical company focused on the in-licensing and development of proprietary product
candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology, today
announced financial results for the third quarter ended September 30, 2006. (pdf)
November 2, 2006, SOMAXON PHARMACEUTICALS TO REPORT 2006 THIRD QUARTER FINANCIAL RESULTS AND HOST CONFERENCE CALL ON NOVEMBER 9, 2006
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced that it will release its 2006 third quarter financial results after the market closes on Thursday, November 9, 2006. Somaxon management will host a conference call that same afternoon at 4:30 p.m. ET (1:30 p.m. PT) to review the financial results and answer questions. (.pdf)
October 23, 2006, Somaxon Pharmaceuticals’ SILENOR™ Demonstrates
Positive Results in a
Phase 3 Transient Insomnia Clinical Trial
• SILENOR™ Demonstrates Statistically Significant Improvement vs. Placebo in Transient Insomnia
• Primary Endpoint of Latency to Persistent Sleep (LPS)
Demonstrates Sleep Onset Action of SILENOR™
• Represents Second Phase 3 Clinical Trial of SILENOR™ to
Demonstrate Positive Results in the Treatment of Insomnia. Two Remaining Phase 3 Trials Will be Reported by End of 2006
San Diego, CA - Somaxon Pharmaceuticals, Inc. (NASDAQ:
SOMX) today announced positive results from the company’s Phase 3 clinical trial
evaluating SILENOR™ (doxepin HCl) in adults with transient insomnia. SILENOR™
demonstrated statistically significant improvements compared to placebo (p<0.0001) in
the primary endpoint of this trial, Latency to Persistent Sleep (LPS), a measure of sleep
onset. SILENOR™ also produced statistically significant improvements relative to
placebo in multiple secondary endpoints, including measures of both sleep onset and
sleep maintenance. (.pdf)
October 22, 2006, Somaxon Pharmaceuticals to Announce Results of Phase 3 Clinical Trial of SILENOR™ for the Treatment of Transient Insomnia and Host Conference Call
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today said that, tomorrow morning, Monday, October 23, the company plans to issue results from its Phase 3 clinical trial of SILENOR™ (doxepin HCl) for the treatment of transient insomnia. Additionally, Somaxon management will host a conference call Monday morning at 9:00 a.m. Eastern Time to review the results of this Phase 3 trial. (.pdf)
September 19, 2006, Somaxon Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference and UBS Global Life Sciences Conference
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced that it will present at the following two investment community conferences. (.pdf)
September 13, 2006, Somaxon Pharmaceuticals to Present at the Merriman Curhan Ford 2006 Investor Summit
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced that Ken Cohen, president and chief executive officer, will present a company update at the Merriman Curhan Ford 2006 Investor Summit at the Mark Hopkins Hotel, in San Francisco, on Monday, September 18, 2006, at 10:45 a.m. Pacific Time. (.pdf)
September 11, 2006, Somaxon Pharmaceuticals Provides Update on Preclinical and Clinical Programs for SILENOR™
• Genotoxicity studies completed
• Data from remaining Phase 3 trials to be announced by end of 2006
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced that it has completed the genotoxicity studies requested by the U.S. Food and Drug Administration (FDA) for SILENOR™ (doxepin HCl), the company’s lead product candidate for the treatment of insomnia. (.pdf)
September 7, 2006, Somaxon Pharmaceuticals to Present at the ThinkEquity Partners 4th Annual Growth Conference
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced that Ken Cohen, president and chief executive officer, will present a company update at the ThinkEquity Partners 4th Annual Growth Conference at the Ritz-Carlton Hotel, in San Francisco, on Monday, September 11, 2006, at 3:00 p.m. Pacific Time. (.pdf)
August 31, 2006, Somaxon Pharmaceuticals to Present at the Thomas Weisel Partners Healthcare 2006 Conference
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced that Ken Cohen, president and chief executive officer, will present a company update at the Thomas Weisel Partners Healthcare 2006 Conference at the Four Seasons Hotel, in Boston, on Wednesday, September 6, 2006, at 11:30 a.m. Eastern Time. (.pdf)
August 9, 2006, SOMAXON PHARMACEUTICALS REPORTS 2006 SECOND QUARTER FINANCIAL RESULTS
• Second quarter 2006 net loss of $14.7 million or $0.82 per share
• Enrollment in all ongoing SILENOR™ and nalmefene clinical trials complete
SAN DIEGO, CA −Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX) today
announced financial results for the second quarter ended June 30, 2006. (.pdf)
July 26, 2006, Somaxon Pharmaceuticals Reports Positive Results From a Pilot Phase 2 Study of Oral Nalmefene in Smoking Cessation
SAN DIEGO, CA − Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced that oral nalmefene hydrochloride, an opiate antagonist under development by the company, demonstrated positive results in a pilot Phase 2 clinical trial for smoking cessation. In a single center, randomized, placebo-controlled study in which 76 smokers were enrolled, patients in the nalmefene 40mg group demonstrated numerically higher abstinence rates at all timepoints relative to placebo. Patients in the nalmefene 80mg group did not consistently achieve abstinence rates that were numerically superior to placebo. The study was not powered to demonstrate statistical significance. (pdf)
July 19, 2006, Somaxon Pharmaceuticals Provides Update on SILENOR™ Development Program for the Treatment of Insomnia
• Preclinical testing required by the FDA
• Anticipated NDA filing now third quarter of 2007
• Results from at least two of remaining three Phase 3 trials expected by end of 2006
SAN DIEGO, CA − Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today is providing information on its development program for SILENOR™ (doxepin HCl), its lead drug candidate currently in Phase 3 clinical trials for the treatment of insomnia. The company is updating information regarding the preclinical testing program for SILENOR™ recently requested by the U.S. Food and Drug Administration (FDA). Based on this information, the company is also updating the anticipated timing of its potential New Drug Application (NDA) submission for SILENOR™. The company is also providing a status update on its ongoing Phase 3 clinical program. (pdf)
July 18, 2006, SOMAXON PHARMACEUTICALS TO REPORT 2006 SECOND QUARTER FINANCIAL RESULTS AND HOST CONFERENCE CALL ON AUGUST 9, 2006
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced that it will release its 2006 second quarter financial results after the market closes on Wednesday, August 9, 2006. Somaxon management will host a conference call that same afternoon at 4:30 p.m. ET (1:30 p.m. PT) to review the financial results and answer questions. (pdf)
June 20, 2006, Somaxon Pharmaceuticals Announces Presentation of Phase 2 SILENOR™ Data at the Associated Professional Sleep Societies Annual Meeting
SAN DIEGO, CA − Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced that data from its Phase 2 clinical trial evaluating three doses of SILENOR™ (doxepin HCL) in elderly adults with insomnia will be presented at the SLEEP 2006 Annual Meeting of the Associated Professional Sleep Societies. The data will be presented by Thomas Roth, Ph.D., Chief, Division Head of the Sleep Disorders & Research Center at Henry Ford Hospital, at the Salt Palace Convention Center in Salt Lake City on Thursday, June 22. The presentation, titled: “Efficacy and Safety of Doxepin 1, 3, and 6mg in Elderly Adults with Primary Insomnia,” will take place at 9:45a.m. in Ballroom FH. (pdf)
June 9, 2006, Somaxon Pharmaceuticals to Present at the Pacific Growth Equities 2006 Life Sciences Growth Conference
SAN DIEGO, CA – June 9, 2006 – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced that Ken Cohen, president and chief executive officer, will present a company update at the Pacific Growth Equities 2006 Life Sciences Growth Conference at the InterContinental Mark Hopkins Hotel, San Francisco, on Wednesday, June 14, 2006, at 1:30 p.m. Pacific Time. (pdf)
May 15, 2006, SOMAXON PHARMACEUTICALS NAMES MATTHEW ONAITIS
VICE PRESIDENT OF LEGAL AFFAIRS
SAN DIEGO, CA − Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced the appointment of Matthew W. Onaitis as vice president of legal affairs, a newly created position. (pdf)
May 10, 2006, SOMAXON PHARMACEUTICALS REPORTS 2006 FIRST QUARTER FINANCIAL RESULTS
SAN DIEGO, CA − Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced financial results for the first quarter ended March 31, 2006. (pdf)
May 3, 2006, Somaxon Pharmaceuticals to Report 2006 First Quarter Financial Results and Host Conference Call on May 10, 2006
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced that it will release its 2006 first quarter financial results after the market closes on Wednesday, May 10, 2006. Somaxon management will host a conference call that same afternoon at 4:30 p.m. EDT (1:30 p.m. PDT) to review the financial results and answer questions. (pdf)
April 27, 2006, Somaxon Pharmaceuticals To Present At The Morgan Stanley Global Healthcare Unplugged Conference
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc.,
(NASDAQ: SOMX) today announced that Kenneth Cohen, President and Chief Executive Officer, will present a company update at the Morgan Stanley Global Healthcare Unplugged Conference in Miami on Friday, May 5, 2006 at 9:30 a.m. Eastern Time. The presentation will take place at the Mandarin Oriental Miami Hotel, in the Singapore Ballroom. (pdf)
April 18, 2006, Somaxon Pharmaceuticals To Present At
The UBS Global Specialty Pharmaceuticals Conference
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc., (NASDAQ: SOMX) today announced that Kenneth Cohen, President and Chief Executive Officer, will present a company update at the UBS Global Specialty Pharmaceuticals Conference in New York City on Tuesday, April 25, 2006 at 3:30 p.m. Eastern Time. The presentation will take place at the Grand Hyatt Hotel Ballroom E. (pdf)
April 10, 2006, Somaxon Pharmaceuticals Announces Positive Phase 3 Results with SILENOR™ for the Treatment of Adults with Chronic Insomnia
• SILENOR ™ demonstrated statistically significant improvements in the primary
endpoint: Wake After Sleep Onset
• Significant improvements were also demonstrated in key secondary endpoints, including
Latency to Persistent Sleep, Total Sleep Time, and Sleep Efficiency
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX),
today announced positive results from its initial Phase 3 clinical trial with the tested doses of
3 mg and 6 mg of SILENOR™ (doxepin HCl), achieving statistically significant results in
adults with chronic insomnia. (pdf)
April 9, 2006, Somaxon Pharmaceuticals to Announce Results of Initial Phase 3 Clinical Trial of SILENOR™ for the Treatment of Adults with Chronic Insomnia and Host Conference Call on Monday, April 10
SAN DIEGO, CA − Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today said that, tomorrow morning, Monday, April 10, the company plans to issue results from its initial Phase 3 clinical trial of SILENOR™ (doxepin HCl) for the treatment of adults with chronic insomnia. Additionally, Somaxon management will host a conference call Monday morning at 8:30 a.m. Eastern Time to review the results of this Phase 3 trial. (pdf)
March 21, 2006, SOMAXON PHARMACEUTICALS REPORTS 2005 FULL-YEAR FINANCIAL RESULTS
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced its financial results for the full year ended December 31, 2005. In December 2005, the company completed its initial public offering of 5,000,000 shares at $11.00 per share. (pdf)
March 14, 2006, SOMAXON PHARMACEUTICALS TO REPORT 2005 FINANCIAL RESULTS AND HOST CONFERENCE CALL ON MARCH 21, 2006
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced that it will release its 2005 financial results after the market closes on Tuesday, March 21, 2006. Somaxon management will host a conference call that same afternoon at 4:30 p.m. EST (1:30 p.m. PST) to review the financial results and answer questions. (pdf)
February 15, 2006, Somaxon Pharmaceuticals, Inc. To Present At The 18 th Annual Roth Capital Partners Growth Stock Conference
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc., (NASDAQ: SOMX) today announced that Kenneth Cohen, President and Chief Executive Officer, will present a company update at the 18 th Annual Roth Capital Partners Growth Stock Conference in Dana Point, CA on Tuesday, February 21, 2006 at 11:30 a.m. PST. (pdf)
February 3, 2006, The American Journal of Psychiatry Publishes Data on Clinical Trial of Nalmefene in the Treatment of Pathological Gambling
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX), a specialty pharmaceutical company focused on the in-licensing and development of product candidates for the treatment of psychiatric and neurological disorders, today said that the February 2006 issue of the American Journal of Psychiatry features an article which describes the conduct and results of a four-month clinical trial investigating the efficacy and safety of one of its product candidates, oral nalmefene hydrochloride, an opioid antagonist, in reducing pathological gambling-related urges, thoughts and behaviors. (pdf)
January 5, 2006, Somaxon Pharmaceuticals, Inc. To Present At The 24th Annual JPMorgan Healthcare Conference
SAN DIEGO, CA – January 5, 2006 – Somaxon Pharmaceuticals, Inc., (NASDAQ: SOMX) today announced that Kenneth Cohen, President and Chief Executive Officer, will present a company update at the 24th Annual JPMorgan Healthcare Conference in San Francisco, CA on Wednesday, January 11, 2006 at 10:00 a.m. PST. (pdf)
2007 | 2005 | 2004
